Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Lymphoma, Non-Hodgkin 3 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Large B-Cell, Diffuse 2 Breast Neoplasms 2 Urologic Diseases 1 Taste Disorders 1 Renal Insufficiency 1 Recurrence 1 Malnutrition 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma 1 Kidney Neoplasms 1 Kidney Diseases 1 Intracranial Germ Cell Tumors 1 Hypothermia 1 Carcinoma, Renal Cell 1

Interventions

fludarabine phosphate 29 Etoposide 26 pegaspargase 24 Peripheral Blood Stem Cell Transplantation 23 Cyclophosphamide 23 Whole-Body Irradiation 21 Mycophenolic Acid 21 Gemcitabine 19 Busulfan 19 Methotrexate 16 Dexamethasone 16 Tacrolimus 15 Cyclosporine 14 Antilymphocyte Serum 13 Radiotherapy 12 Oxaliplatin 10 Rituximab 9 Melphalan 8 Asparaginase 8 Doxorubicin 7 Bortezomib 7 spartalizumab 6 Vorinostat 6 Lenalidomide 6 Flow Cytometry 6 tislelizumab 5 Vincristine 5 Therapeutics 5 Methylprednisolone 5 Everolimus 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Extranodal NK-T-Cell × Ice × Clear all

NCT04425070 2026-01-05

TOUCH

Antengene Corporation

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡